EUVIMEDEUVIMED entdecken
Crossref

Development and ex-Vivo Evaluation of a Polycaprolactone Nanoparticle-Based Gel for Transdermal Delivery of Itraconazole

Dr. Rihana Begum Patnool, Ashutosh Shukla, Suraj Mandal, Dr. Gyan Ranjan, Dr. Preeti Singh, Dr. Mohammad Badrud Duza

International Journal of Drug Delivery Technology · 24.04.2026 · 16 (18s)

DOI: 10.25258/ijddt.16.18s.99 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 24.04.2026. Verfasst von Dr. Rihana Begum Patnool und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Itraconazole (ITZ) is a potent broad-spectrum antifungal agent whose clinical utility is severely limited by its poor aqueous solubility (BCS Class II) and consequent low oral bioavailability and inadequate topical skin penetration. To overcome these challenges, this study developed and evaluated a novel transdermal delivery system for ITZ based on polymeric nanoparticles. Itraconazole-loaded polycaprolactone nanoparticles (ITZ-PCL-NPs) were synthesized using a nanoprecipitation method, optimized via a Design of Experiments (DoE) approach, and subsequently incorporated into a Carbopol 934P hydrogel. The optimized nanoparticles (Formulation F2) exhibited a spherical morphology, a mean particle size of 154.6 ± 3.2 nm, a high encapsulation efficiency of 88.4 ± 2.1%, and successfully converted the drug to an amorphous state, as confirmed by DSC and XRD. The resulting ITZ-PCL-NP gel demonstrated a sustained, pH-dependent in vitro release profile (94.3% at pH 7.4 vs. 80.4% at pH 5.5 over 24 hours), fitting the Higuchi diffusion model. Crucially, ex vivo skin permeation studies on rat skin showed a 2.32-fold enhancement in steady-state flux (7.22 ± 0.45 µg/cm²/h) compared to a plain ITZ gel. The formulation was nonirritating in the HET-CAM assay and exhibited good physical and chemical stability over three months. In conclusion, the ITZ-PCL-NP gel represents a promising, effective, and safe nanocarrier-based strategy for the enhanced transdermal delivery of itraconazole, addressing its key biopharmaceutical limitations for potential localized therapy of deep-seated fungal infections.

Zitieren

APA

Patnool, D. R. B., Shukla, A., Mandal, S., Ranjan, D. G., Singh, D. P., & Duza, D. M. B. (2026). Development and ex-Vivo Evaluation of a Polycaprolactone Nanoparticle-Based Gel for Transdermal Delivery of Itraconazole. International Journal of Drug Delivery Technology, 16(18s). https://doi.org/10.25258/ijddt.16.18s.99

Vancouver

Patnool DRB, Shukla A, Mandal S, Ranjan DG, Singh DP, Duza DMB. Development and ex-Vivo Evaluation of a Polycaprolactone Nanoparticle-Based Gel for Transdermal Delivery of Itraconazole. International Journal of Drug Delivery Technology. 2026;16(18s). doi:10.25258/ijddt.16.18s.99

BibTeX
@article{Patnool2026,
  author = {Patnool, Dr. Rihana Begum and Shukla, Ashutosh and Mandal, Suraj and Ranjan, Dr. Gyan and Singh, Dr. Preeti and Duza, Dr. Mohammad Badrud},
  title = {Development and ex-Vivo Evaluation of a Polycaprolactone Nanoparticle-Based Gel for Transdermal Delivery of Itraconazole},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {18s},
  doi = {10.25258/ijddt.16.18s.99}
}
Kostenlos starten →